Anti-IL-17 therapy in people living with HIV who have cutaneous psoriasis: A four-patient case series.

AimTo describe the clinical, immunological, virological and safety outcomes observed during anti-IL-17 therapy in patients living with HIV who had cutaneous psoriasis.MethodFour patients living with HIV who had cutaneous psoriasis and were treated with anti-IL-17 agents were included in this case series. Psoriasis Area Severity Index (PASI) scores, CD4 cell counts, HIV RNA levels, treatment duration and adverse events were obtained from medical records.ResultsThree patients received secukinumab and one received ixekizumab. Psoriasis improved in all four patients. CD4 cell counts remained stable or increased, while HIV RNA levels remained suppressed or declined following antiretroviral therapy. No adverse events were observed during follow-up.ConclusionAnti-IL-17 therapy was associated with clinical improvement without observed deterioration in immunological or virological parameters in this small case series. Larger prospective studies are required before conclusions regarding safety can be drawn.